About MEI Pharma
MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: MEIP
- Previous Close: $1.74
- 50 Day Moving Average: $1.51
- 200 Day Moving Average: $1.64
- 52-Week Range: $36,772,000.00 - $1.07
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.25
- P/E Growth: 860.00
- Market Cap: $63.98M
- Outstanding Shares: 36,772,000
- Beta: 1.01
- Return on Equity: -7.59%
- Return on Assets: -6.49%
Companies Related to MEI Pharma:
- Current Ratio: 17.42%
- Quick Ratio: 17.42%
What is MEI Pharma's stock symbol?
MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."
Where is MEI Pharma's stock going? Where will MEI Pharma's stock price be in 2017?
1 brokers have issued 12-month target prices for MEI Pharma's shares. Their predictions range from $2.00 to $2.00. On average, they expect MEI Pharma's stock price to reach $2.00 in the next twelve months.
When will MEI Pharma announce their earnings?
MEI Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, February, 8th 2017.
Who owns MEI Pharma stock?
MEI Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.68%), Interwest Venture Management Co. (1.58%), Ancora Advisors LLC (0.88%) and FMR LLC (0.86%).
Who sold MEI Pharma stock? Who is selling MEI Pharma stock?
MEI Pharma's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Ancora Advisors LLC.
Who bought MEI Pharma stock? Who is buying MEI Pharma stock?
MEI Pharma's stock was bought by a variety of institutional investors in the last quarter, including Interwest Venture Management Co. and FMR LLC.
How do I buy MEI Pharma stock?
Shares of MEI Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of MEI Pharma stock cost?
One share of MEI Pharma stock can currently be purchased for approximately $1.74.